

IMP-3 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP6763c

Specification

IMP-3 Antibody (Center) Blocking Peptide - Product Information

Primary Accession

000425

IMP-3 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 10643

Other Names

Insulin-like growth factor 2 mRNA-binding protein 3, IGF2 mRNA-binding protein 3, IMP-3, IGF-II mRNA-binding protein 3, KH domain-containing protein overexpressed in cancer, hKOC, VICKZ family member 3, IGF2BP3, IMP3, KOC1, VICKZ3

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP6763c was selected from the Center region of human IMP-3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.


IMP-3 Antibody (Center) Blocking Peptide - Protein Information

Name IGF2BP3

Synonyms IMP3, KOC1, VICKZ3

Function

RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6- methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by





binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs.

Cellular Location

Nucleus. Cytoplasm, Cytoplasm, P-body. Cytoplasm, Stress granule. Note=Found in lamellipodia of the leading edge, in the perinuclear region, and beneath the plasma membrane. The subcytoplasmic localization is cell specific and regulated by cell contact and growth. Localized at the connecting piece and the tail of the spermatozoa. Colocalized with CD44 mRNA in RNP granules. In response to cellular stress, such as oxidative stress, recruited to stress granules

Tissue Location

Expressed in fetal liver, fetal lung, fetal kidney, fetal thymus, fetal placenta, fetal follicles of ovary and gonocytes of testis, growing oocytes, spermatogonia and semen (at protein level) Expressed in cervix adenocarcinoma, in testicular, pancreatic and renal-cell carcinomas (at protein level). Expressed ubiquitously during fetal development at 8 and 14 weeks of gestation. Expressed in ovary, testis, brain, placenta, pancreatic cancer tissues and pancreatic cancer cell lines.

IMP-3 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

IMP-3 Antibody (Center) Blocking Peptide - Images

IMP-3 Antibody (Center) Blocking Peptide - Background

IGF2BP3 is primarily found in the nucleolus, where it can bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may repress translation of insulin-like growth factor II during late development. This protein contains several KH domains, which are important in RNA binding and are known to be involved in RNA synthesis and metabolism.

IMP-3 Antibody (Center) Blocking Peptide - References

Kobel, M., et.al., Mod. Pathol. 22 (3), 469-475 (2009)